Hypothesis: Intermittent mTOR Inhibition Combined with Senolytic Pulse Therapy Restores Regenerative Capacity of Aged c‑Kit+ Cardiac Progenitor Cells More Effectively Than Either Approach Alone

Core idea Continuous mTOR inhibition (e.g., rapamycin) pushes aged c‑Kit+ CPCs into a metabolically quiescent, stress‑resistant state that delays senescence but does not permit the proliferative bursts needed for myocardial repair. Senolytic agents clear the SASP‑producing subset of these cells, improving the niche. However, removing senescent cells while keeping mTOR chronically suppressed may leave the remaining progenitors unable to transition from quiescence to proliferation when injury signals arrive. We hypothesize that intermittent mTOR inhibition—providing windows of mTOR activity—paired with periodic senolytic pulses will (1) keep the progenitor pool in a protected, low‑SASP state most of the time, and (2) allow transient mTOR‑driven proliferation after injury, thereby enhancing functional recovery.

Mechanistic rationale

• mTORC1 inhibition boosts autophagy and fatty‑acid oxidation, suppressing the translation of SASP components and promoting a quiescent phenotype [1][2].
• The same inhibition reduces phosphorylation of 4E‑BP1 and S6K, limiting cap‑dependent translation of cyclins (D1, E1) and CDKs that are required for G1‑S transition [3].
• Senolytic clearance (dasatinib + quercetin) eliminates cells with high p16^INK4a^ and SASP, lowering paracrine inhibition of neighboring progenitors [4].
• When mTOR activity is briefly restored (e.g., 24 h rapamycin washout before an ischemic insult), S6K signaling rebounds, driving mitochondrial biogenesis and cyclin expression, enabling progenitors to enter the cell cycle and contribute to new cardiomyocytes [5].

Testable predictions

1. In aged mice, groups receiving intermittent rapamycin (3 days on/4 days off) plus weekly senolytic injections will show:
   • Lower SA‑β‑gal^+^ and p16^INK4a^^ frequencies in c‑Kit+ CPCs vs. continuous rapamycin or senolytic alone.
   • Higher Ki‑67^+^ progenitor cells 48 h after myocardial ischemia‑reperfusion injury.
   • Improved ejection fraction (+15 % vs. baseline) and reduced fibrosis at 4 weeks post‑injury.
2. Continuous rapamycin alone will maintain low SASP but fail to increase Ki‑67^+^ progenitors after injury.
3. Senolytic alone will reduce SASP but not improve proliferative response due to persistent mTOR‑mediated translational block.

Experimental outline

• Use 20‑month‑old C57BL/6J mice, stratify into six n=10 groups: (1) vehicle, (2) continuous rapamycin (2 mg/kg chow), (3) intermittent rapamycin (same dose 3 on/4 off), (4) weekly senolytic (D 5 mg/kg + Q 50 mg/kg), (5) intermittent rapamycin + senolytic, (6) intermittent rapamycin + senolytic with rapamycin withdrawn 24 h before ischemia‑reperfusion.
• Assess c‑Kit+ CPCs by flow cytometry (c‑Kit^+^Sca‑1^+^) for senescence markers, mitochondrial mass (MitoTracker), and proliferation (Ki‑67, EdU).
• Perform transient left anterior descending coronary artery ligation, measure echocardiography at baseline, 24 h, and 4 weeks.
• Quantify fibrosis (Masson’s trichrome) and cytokine profile (IL‑6, MCP‑1) in myocardium.

Falsifiability If intermittent mTOR inhibition combined with senolysis does not yield superior progenitor proliferation or functional improvement compared with each monotherapy, the hypothesis is refuted. Conversely, a clear additive benefit supports the notion that lifespan‑extending mTOR inhibition must be coupled with periodic clearance of senescent cells to transition from metabolic mimicry to genuine regenerative repair.